Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
View original at finance.yahoo.comCell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals Precedence Research This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Zolgensma is one of the highest-grossing gene therapies in the world
80% confidence9 new gene and cell therapies were approved by the FDA in 2024
80% confidenceYescarta is currently one of the top-selling therapies in the CAR-T category
80% confidenceAs of 2025, there are 36 approved gene therapies globally and 71 non-genetically modified cell therapies
80% confidenceIndia's growing role in global gene therapy production is evidenced by Bharat Biotech's expansion into gene therapies and CGT manufacturing capabilities
80% confidenceThe FDA has approved 7 distinct CAR-T products
80% confidenceZolgensma projected sales are estimated at $510 million by 2027
80% confidenceThere are 46 FDA-approved cell and gene therapies in the U.S.
80% confidenceThe cell and gene therapy market will hit $232.22 billion by 2035, driven by a CAGR of 24% over the forecast period
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · approved car t products | 7 products |
| U.S. Food and Drug Administration · approved gene therapies global | 36 products |
| U.S. Food and Drug Administration · approved non modified cell therapies | 71 products |
| U.S. Food and Drug Administration · new approvals | 9 products |